Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

Originally published as JCO Early Release 10.1200/JCO.2007.14.5482 on March 10 2008

Journal of Clinical Oncology, Vol 26, No 10 (April 1), 2008: pp. 1603-1610
© 2008 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Tabernero, J.
Right arrow Articles by Baselga, J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tabernero, J.
Right arrow Articles by Baselga, J.
Related Articles
Right arrowRelated Articles
Right arrowRelated Editorial

Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

Josep Tabernero, Federico Rojo, Emiliano Calvo, Howard Burris, Ian Judson, Katharine Hazell, Erika Martinelli, Santiago Ramon y Cajal, Suzanne Jones, Laura Vidal, Nicholas Shand, Teresa Macarulla, Francisco Javier Ramos, Sasa Dimitrijevic, Ulrike Zoellner, Pui Tang, Michael Stumm, Heidi A. Lane, David Lebwohl, José Baselga

From the Medical Oncology and Pathology Departments, Vall d’Hebron University Hospital, Barcelona, Spain; Medical Oncology Department, Sarah Cannon Cancer Center, Nashville, TN; Medical Oncology Department, Royal Marsden Hospital, London, United Kingdom; Novartis Oncology, Basel, Switzerland; and Novartis Oncology, Florham Park, NJ

Corresponding author: José Baselga, MD, Medical Oncology Department, Vall d’Hebron University Hospital, P. Vall d’Hebron, 119-129, 08035, Barcelona, Spain; e-mail: jbaselga{at}vhebron.net

Purpose: Everolimus is a selective mammalian target of rapamycin (mTOR) inhibitor with promising anticancer activity. In order to identify a rationally based dose and schedule for cancer treatment, we have conducted a tumor pharmacodynamic phase I study in patients with advanced solid tumors.

Patients and Methods: Fifty-five patients were treated with everolimus in cohorts of 20, 50, and 70 mg weekly or 5 and 10 mg daily. Dose escalation depended on dose limiting toxicity (DLT) rate during the first 4-week period. Pre- and on-treatment steady-state tumor and skin biopsies were evaluated for total and phosphorylated (p) protein S6 kinase 1, eukaryotic initiation factor 4E (elF-4E) binding protein 1 (4E-BP1), eukaryotic initiation factor 4G (eIF-4G), AKT, and Ki-67 expression. Plasma trough levels of everolimus were determined on a weekly basis before dosing during the first 4 weeks.

Results: We observed a dose- and schedule-dependent inhibition of the mTOR pathway with a near complete inhibition of pS6 and peIF-4G at 10 mg/d and ≥ 50 mg/wk. In addition, pAKT was upregulated in 50% of the treated tumors. In the daily schedule, there was a correlation between everolimus plasma trough concentrations and inhibition of peIF4G and p4E-BP1. There was good concordance of mTOR pathway inhibition between skin and tumor. Clinical benefit was observed in four patients including one patient with advanced colorectal cancer achieving a partial response. DLTs occurred in five patients: one patient at 10 mg/d (grade 3 stomatitis) and four patients at 70 mg/wk (two with grade 3 stomatitis, one with grade 3 neutropenia, and one with grade 3 hyperglycemia).

Conclusion: Everolimus achieved mTOR signaling inhibition at doses below the DLT. A dosage of 10 mg/d or 50 mg/wk is recommended for further development.

Submitted September 20, 2007; accepted November 16, 2007.

Presented in part at the 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13-17, 2005; and at the 13th European Cancer Conference, Paris, France, October 30 to November 3, 2005.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Related Articles

  • Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors
    Anne O'Donnell, Sandrine Faivre, Howard A. Burris, III, Daniel Rea, Vassiliki Papadimitrakopoulou, Nicholas Shand, Heidi A. Lane, Katharine Hazell, Ulrike Zoellner, John M. Kovarik, Cathryn Brock, Suzanne Jones, Eric Raymond, and Ian Judson
    JCO 2008 26: 1588-1595 [Abstract] [Full Text]
  • Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data
    Chiaki Tanaka, Terence O’Reilly, John M. Kovarik, Nicholas Shand, Katharine Hazell, Ian Judson, Eric Raymond, Sabine Zumstein-Mecker, Christine Stephan, Anne Boulay, Marc Hattenberger, George Thomas, and Heidi A. Lane
    JCO 2008 26: 1596-1602 [Abstract] [Full Text]

Related Editorial

  • Dose Selection in Phase I Studies: Why We Should Always Go for the Top
    Stefan Sleijfer and Erik Wiemer
    JCO 2008 26: 1576-1578 [Full Text]


This article has been cited by other articles:


Home page
JCOHome page
I. E. Haines
Dose Selection in Phase I Studies: Why We Should Always Go for the Most Effective
J. Clin. Oncol., July 20, 2008; 26(21): 3650 - 3652.
[Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
J. R. Hecht
Current and emerging therapies for metastatic colorectal cancer: Applying research findings to clinical practice
Am. J. Health Syst. Pharm., June 1, 2008; 65(11_Supplement_4): S15 - S21.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. Tanaka, T. O'Reilly, J. M. Kovarik, N. Shand, K. Hazell, I. Judson, E. Raymond, S. Zumstein-Mecker, C. Stephan, A. Boulay, et al.
Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data
J. Clin. Oncol., April 1, 2008; 26(10): 1596 - 1602.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 Site Map

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online